AIM ImmunoTech Inc. (AIM) 10-Year Financial Performance & Capital Metrics

AIM • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutAIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Show more

Revenue $170K -15.8%
EBITDA -$20M +38.4%
Net Income -$17M +40.2%
EPS (Diluted) -0.31 +48.3%
Gross Margin 81.76% +3.2%
EBITDA Margin -11485.88% +26.8%
Operating Margin -11630.59% +26.4%
Net Margin -10188.24% +28.9%
ROE -388.69% -226.8%
ROIC -546.09% -102.6%
Debt/Equity -
Interest Coverage -33.80

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 15.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.46%

5Y3.96%

3Y7.99%

TTM-41.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM34.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1027.58%

ROCE

10Y Avg-105.37%

5Y Avg-123.79%

3Y Avg-190.97%

Latest-403.43%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	133K	92K	437K	367K	140K	163K	135K	141K	202K	170K
Revenue Growth %	-0.32%	-0.31%	3.75%	-0.16%	-0.62%	0.16%	-0.17%	0.04%	0.43%	-0.16%
Cost of Goods Sold+	1.6M	1.11M	1.18M	884K	893K	806K	850K	-424K	42K	31K
COGS % of Revenue	12.02%	12.04%	2.71%	2.41%	6.38%	4.94%	6.3%	-3.01%	0.21%	0.18%
Gross Profit+	-1.47M	-1.02M	-746K	-517K	-753K	-643K	-715K	565K	160K	139K
Gross Margin %	-11.02%	-11.04%	-1.71%	-1.41%	-5.38%	-3.94%	-5.3%	4.01%	0.79%	0.82%
Gross Profit Growth %	-0.39%	0.31%	0.27%	0.31%	-0.46%	0.15%	-0.11%	1.79%	-0.72%	-0.13%
Operating Expenses+	15.19M	12.79M	10.67M	10.98M	11.69M	14.51M	18.12M	20.49M	32.08M	19.91M
OpEx % of Revenue	114.17%	139%	24.42%	29.92%	83.5%	89.01%	134.24%	145.3%	158.79%	117.12%
Selling, General & Admin	7.15M	7.68M	6.57M	6.2M	7.04M	8.65M	8.67M	13.5M	21.14M	13.71M
SG&A % of Revenue	53.74%	83.49%	15.04%	16.9%	50.28%	53.09%	64.24%	95.73%	104.64%	80.67%
Research & Development	8.04M	5.11M	4.1M	4.78M	4.65M	5.72M	7.67M	6.99M	10.93M	6.2M
R&D % of Revenue	60.44%	55.51%	9.38%	13.02%	33.22%	35.09%	56.83%	49.57%	54.08%	36.45%
Other Operating Expenses	0	0	0	0	0	135K	1.78M	0	0	0
Operating Income+	-16.65M	-13.8M	-11.42M	-11.5M	-12.44M	-15.15M	-18.84M	-19.92M	-31.92M	-19.77M
Operating Margin %	-125.19%	-150.04%	-26.12%	-31.32%	-88.88%	-92.96%	-139.54%	-141.3%	-158%	-116.31%
Operating Income Growth %	0.13%	0.17%	0.17%	-0.01%	-0.08%	-0.22%	-0.24%	-0.06%	-0.6%	0.38%
EBITDA+	-15.46M	-12.63M	-10.41M	-10.58M	-11.61M	-14.42M	-18.06M	-20.35M	-31.68M	-19.53M
EBITDA Margin %	-116.24%	-137.34%	-23.83%	-28.82%	-82.96%	-88.46%	-133.8%	-144.3%	-156.82%	-114.86%
EBITDA Growth %	0.14%	0.18%	0.18%	-0.02%	-0.1%	-0.24%	-0.25%	-0.13%	-0.56%	0.38%
D&A (Non-Cash Add-back)	1.19M	1.17M	1M	920K	829K	733K	775K	-424K	238K	246K
EBIT	-15.23M	-7.5M	-8.12M	-9.32M	-8.98M	-13.73M	-19.06M	-19.45M	-28.96M	-16.73M
Net Interest Income+	361K	129K	-51K	-470K	-338K	-453K	-67K	629K	0	4.61M
Interest Income	364K	129K	88K	32K	89K	219K	0	629K	0	5.19M
Interest Expense	3K	0	139K	502K	427K	672K	67K	0	0	585K
Other Income/Expense	1.42M	6.3M	3.16M	1.67M	3.04M	752K	-289K	477.81K	2.95M	2.45M
Pretax Income+	-15.23M	-7.5M	-8.26M	-9.81M	-9.53M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Pretax Margin %	-114.51%	-81.54%	-18.9%	-26.74%	-68.09%	-88.34%	-141.68%	-137.91%	-143.38%	-101.88%
Income Tax+	3K	0	0	2.19M	1.29M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.14%	1%	1%	1%	1%	1%
Net Income+	-15.23M	-7.5M	-8.26M	-9.81M	-10.83M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Net Margin %	-114.51%	-81.54%	-18.9%	-26.74%	-77.33%	-88.34%	-141.68%	-137.91%	-143.38%	-101.88%
Net Income Growth %	0.13%	0.51%	-0.1%	-0.19%	-0.1%	-0.33%	-0.33%	-0.02%	-0.49%	0.4%
Net Income (Continuing)	-15.23M	-7.5M	-8.26M	-9.83M	-9.4M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-34.05	-15.13	-12.67	-9.77	-2.97	-0.51	-0.45	-0.44	-0.60	-0.31
EPS Growth %	0.3%	0.56%	0.16%	0.23%	0.7%	0.83%	0.12%	0.02%	-0.36%	0.48%
EPS (Basic)	-34.05	-15.13	-12.67	-9.77	-2.97	-0.51	-0.45	-0.44	-0.60	-0.31
Diluted Shares Outstanding	447.25K	495.86K	651.72K	1M	3.64M	31.84M	47.34M	48.05M	48.59M	56.02M
Basic Shares Outstanding	447.25K	495.86K	651.72K	1M	3.64M	31.84M	47.34M	48.05M	48.59M	56.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.57M	6.94M	3.5M	3.8M	10.45M	40.31M	50.21M	36.32M	14.56M	4.18M
Cash & Short-Term Investments	8.91M	5.87M	2.11M	1.82M	8.78M	39M	48.27M	34.19M	13.07M	3.98M
Cash Only	2.12M	2.41M	1.41M	299K	1.47M	38.5M	32.09M	27.05M	5.44M	1.7M
Short-Term Investments	6.79M	3.46M	695K	1.53M	7.31M	501K	16.18M	7.14M	7.63M	2.28M
Accounts Receivable	0	0	24K	1.09M	820K	1.12M	1.64M	1.68M	1.18M	0
Days Sales Outstanding	-	-	20.05	1.09K	2.14K	2.52K	4.44K	4.34K	2.14K	-
Inventory	1.33M	0	0	0	0	0	0	0	-302K	0
Days Inventory Outstanding	302.87	-	-	-	-	-	-	-	-	-
Other Current Assets	0	764K	764K	0	0	184K	0	455K	302K	199K
Total Non-Current Assets+	12.23M	11.93M	10.7M	10.05M	9.77M	70.71M	7.49M	4.17M	4.83M	4.43M
Property, Plant & Equipment	11.24M	9.51M	8.59M	7.78M	7.27M	6.65M	4.2M	1.02M	824K	726K
Fixed Asset Turnover	0.01x	0.01x	0.05x	0.05x	0.02x	0.02x	0.03x	0.14x	0.25x	0.23x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	862K	872K	858K	912K	1.15M	1.5M	1.97M	1.94M	2.31M	2.59M
Long-Term Investments	0	0	0	-40.29M	-45.09M	15.38M	-25.02M	0	0	0
Other Non-Current Assets	134K	1.55M	1.26M	1.35M	1.35M	116K	1.32M	1.2M	1.69M	1.11M
Total Assets+	22.8M	18.87M	14.21M	13.85M	20.22M	111.02M	57.7M	40.49M	19.38M	8.61M
Asset Turnover	0.01x	0.00x	0.03x	0.03x	0.01x	0.00x	0.00x	0.00x	0.01x	0.02x
Asset Growth %	-0.23%	-0.17%	-0.25%	-0.03%	0.46%	4.49%	-0.48%	-0.3%	-0.52%	-0.56%
Total Current Liabilities+	2.43M	2.44M	2.71M	5.29M	1.13M	1.1M	673K	1.36M	8.65M	9.54M
Accounts Payable	1.21M	887K	741K	680K	472K	383K	198K	377K	6.44M	6.38M
Days Payables Outstanding	277.06	292.2	228.63	280.77	192.92	173.44	85.02	-324.54	55.99K	75.15K
Short-Term Debt	0	0	0	3.61M	214K	277K	0	0	0	2.31M
Deferred Revenue (Current)	0	0	0	806K	189K	0	0	0	0	0
Other Current Liabilities	0	0	0	0	309K	440K	0	1K	1.57M	1K
Current Ratio	4.34x	2.85x	1.29x	0.72x	9.27x	36.58x	74.61x	26.69x	1.68x	0.44x
Quick Ratio	3.80x	2.85x	1.29x	0.72x	9.27x	36.58x	74.61x	26.69x	1.72x	0.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	940K	2.8M	3.38M	6.18M	48.63M	147K	659K	495K	395K
Long-Term Debt	0	0	1.83M	0	3.91M	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.32M	2.22M	2.01M	112K	659K	495K	395K
Deferred Tax Liabilities	0	0	0	40.29M	44.56M	46.44M	23.71M	0	0	0
Other Non-Current Liabilities	0	940K	962K	1.06M	57K	180K	35K	0	0	0
Total Liabilities	2.43M	3.38M	5.5M	8.67M	7.31M	49.73M	820K	2.02M	9.15M	9.93M
Total Debt+	1K	0	1.83M	5.92M	6.38M	2.29M	149K	837K	718K	2.94M
Net Debt	-2.11M	-2.41M	423K	5.63M	4.91M	-36.22M	-31.94M	-26.22M	-4.72M	1.24M
Debt / Equity	0.00x	-	0.21x	1.15x	0.49x	0.04x	0.00x	0.02x	0.07x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-5550.00x	-	-82.13x	-22.90x	-29.14x	-22.55x	-281.16x	-	-	-33.80x
Total Equity+	20.37M	15.5M	8.7M	5.17M	12.91M	61.29M	56.88M	38.47M	10.23M	-1.32M
Equity Growth %	-0.19%	-0.24%	-0.44%	-0.41%	1.49%	3.75%	-0.07%	-0.32%	-0.73%	-1.13%
Book Value per Share	45.55	31.25	13.35	5.15	3.54	1.92	1.20	0.80	0.21	-0.02
Total Shareholders' Equity	20.37M	15.5M	8.7M	5.17M	12.91M	61.29M	56.88M	38.47M	10.23M	-1.32M
Common Stock	247K	24K	33K	49K	10K	42K	48K	48K	49K	66K
Retained Earnings	-293M	-300.5M	-308.76M	-318.57M	-328.11M	-341.97M	-361.1M	-380.55M	-409.51M	-426.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-97K	-5K	11K	-3K	0	-47K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.05M	-7.38M	-7.94M	-10.64M	-9.07M	-10.37M	-13.96M	-16.11M	-21.27M	-14.89M
Operating CF Margin %	-120.7%	-80.22%	-18.17%	-28.99%	-64.76%	-63.61%	-103.44%	-114.24%	-105.28%	-87.58%
Operating CF Growth %	-0.15%	0.54%	-0.08%	-0.34%	0.15%	-0.14%	-0.35%	-0.15%	-0.32%	0.3%
Net Income	-15.23M	-7.5M	-8.26M	-9.81M	-9.53M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Depreciation & Amortization	1.19M	1.3M	1.01M	878K	792K	733K	805K	256K	238K	246K
Stock-Based Compensation	181K	410K	571K	929K	853K	1.04M	1.57M	954K	243K	686K
Deferred Taxes	0	57K	-17K	-1.4M	-891K	-96K	-2.32M	197K	5.84M	0
Other Non-Cash Items	378K	-1.68M	-2.38M	845K	255K	1.75M	4.24M	964K	310K	1.2M
Working Capital Changes	-2.57M	29K	1.13M	-2.08M	-543K	605K	895K	966K	1.06M	296K
Change in Receivables	0	0	-24K	-1.07M	274K	40K	34K	-35K	492K	1.18M
Change in Inventory	-1.33M	-1.33M	0	0	-647K	0	0	35K	0	0
Change in Payables	-196K	-326K	566K	166K	-207K	-89K	-185K	179K	0	-60K
Cash from Investing+	6.35M	2.92M	2.73M	92K	-6.15M	-9.16M	-631K	10.99M	-832K	4.71M
Capital Expenditures	-490K	-454K	-69K	-127K	-365K	-595K	-633K	-271K	-585K	-18K
CapEx % of Revenue	3.68%	4.93%	0.16%	0.35%	2.61%	3.65%	4.69%	1.92%	2.9%	0.11%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1.13M	0	-573K	-347K	0	0	-631K
Cash from Financing+	9.66M	4.76M	4.21M	9.44M	16.39M	56.56M	8.19M	80K	485K	6.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	4.76M	-102K	4.52M	0	0	0	0	0	3.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.54M	-7.83M	-8.01M	-10.77M	-9.43M	-10.96M	-14.6M	-16.38M	-21.85M	-14.91M
FCF Margin %	-124.38%	-85.15%	-18.33%	-29.34%	-67.37%	-67.26%	-108.13%	-116.16%	-108.18%	-87.68%
FCF Growth %	-0.13%	0.53%	-0.02%	-0.34%	0.12%	-0.16%	-0.33%	-0.12%	-0.33%	0.32%
FCF per Share	-36.99	-15.80	-12.29	-10.72	-2.59	-0.34	-0.31	-0.34	-0.45	-0.27
FCF Conversion (FCF/Net Income)	1.05x	0.98x	0.96x	1.08x	0.84x	0.72x	0.73x	0.83x	0.73x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-67.13%	-41.83%	-68.25%	-141.43%	-119.75%	-38.81%	-32.37%	-40.79%	-118.94%	-388.69%
Return on Invested Capital (ROIC)	-60.73%	-66.05%	-77.08%	-86.54%	-65.22%	-52.99%	-56.5%	-80.36%	-269.48%	-546.09%
Gross Margin	-1101.5%	-1104.35%	-170.71%	-140.87%	-537.86%	-394.48%	-529.63%	400.71%	79.21%	81.76%
Net Margin	-11451.13%	-8154.35%	-1889.93%	-2673.84%	-7732.86%	-8834.36%	-14168.15%	-13790.78%	-14337.62%	-10188.24%
Debt / Equity	0.00x	-	0.21x	1.15x	0.49x	0.04x	0.00x	0.02x	0.07x	-
Interest Coverage	-5550.00x	-	-82.13x	-22.90x	-29.14x	-22.55x	-281.16x	-	-	-33.80x
FCF Conversion	1.05x	0.98x	0.96x	1.08x	0.84x	0.72x	0.73x	0.83x	0.73x	0.86x
Revenue Growth	-32.49%	-30.83%	375%	-16.02%	-61.85%	16.43%	-17.18%	4.44%	43.26%	-15.84%

Revenue by Segment

	2020	2021	2022
Clinical Treatment Programs - US	-	-	141K
Clinical Treatment Programs - US Growth	-	-	-
Clinical Treatment Programs U S	-	135K	-
Clinical Treatment Programs U S Growth	-	-	-

Revenue by Geography

	2020	2021	2022
United States	144K	-	-
United States Growth	-	-	-
Europe	19K	-	-
Europe Growth	-	-	-

Frequently Asked Questions

Growth & Financials

AIM ImmunoTech Inc. (AIM) reported $0.1M in revenue for fiscal year 2024. This represents a 30% decrease from $0.2M in 2011.

AIM ImmunoTech Inc. (AIM) saw revenue decline by 15.8% over the past year.

AIM ImmunoTech Inc. (AIM) reported a net loss of $15.8M for fiscal year 2024.

Dividend & Returns

AIM ImmunoTech Inc. (AIM) has a return on equity (ROE) of -388.7%. Negative ROE indicates the company is unprofitable.

AIM ImmunoTech Inc. (AIM) had negative free cash flow of $13.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

AIM ImmunoTech Inc. (AIM) 10-Year Financial Performance & Capital Metrics

AIM • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $170K -15.8%
EBITDA -$20M +38.4%
Net Income -$17M +40.2%
EPS (Diluted) -0.31 +48.3%
Gross Margin 81.76% +3.2%
EBITDA Margin -11485.88% +26.8%
Operating Margin -11630.59% +26.4%
Net Margin -10188.24% +28.9%
ROE -388.69% -226.8%
ROIC -546.09% -102.6%
Debt/Equity -
Interest Coverage -33.80

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 15.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.46%

5Y3.96%

3Y7.99%

TTM-41.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM34.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1027.58%

ROCE

10Y Avg-105.37%

5Y Avg-123.79%

3Y Avg-190.97%

Latest-403.43%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	133K	92K	437K	367K	140K	163K	135K	141K	202K	170K
Revenue Growth %	-0.32%	-0.31%	3.75%	-0.16%	-0.62%	0.16%	-0.17%	0.04%	0.43%	-0.16%
Cost of Goods Sold+	1.6M	1.11M	1.18M	884K	893K	806K	850K	-424K	42K	31K
COGS % of Revenue	12.02%	12.04%	2.71%	2.41%	6.38%	4.94%	6.3%	-3.01%	0.21%	0.18%
Gross Profit+	-1.47M	-1.02M	-746K	-517K	-753K	-643K	-715K	565K	160K	139K
Gross Margin %	-11.02%	-11.04%	-1.71%	-1.41%	-5.38%	-3.94%	-5.3%	4.01%	0.79%	0.82%
Gross Profit Growth %	-0.39%	0.31%	0.27%	0.31%	-0.46%	0.15%	-0.11%	1.79%	-0.72%	-0.13%
Operating Expenses+	15.19M	12.79M	10.67M	10.98M	11.69M	14.51M	18.12M	20.49M	32.08M	19.91M
OpEx % of Revenue	114.17%	139%	24.42%	29.92%	83.5%	89.01%	134.24%	145.3%	158.79%	117.12%
Selling, General & Admin	7.15M	7.68M	6.57M	6.2M	7.04M	8.65M	8.67M	13.5M	21.14M	13.71M
SG&A % of Revenue	53.74%	83.49%	15.04%	16.9%	50.28%	53.09%	64.24%	95.73%	104.64%	80.67%
Research & Development	8.04M	5.11M	4.1M	4.78M	4.65M	5.72M	7.67M	6.99M	10.93M	6.2M
R&D % of Revenue	60.44%	55.51%	9.38%	13.02%	33.22%	35.09%	56.83%	49.57%	54.08%	36.45%
Other Operating Expenses	0	0	0	0	0	135K	1.78M	0	0	0
Operating Income+	-16.65M	-13.8M	-11.42M	-11.5M	-12.44M	-15.15M	-18.84M	-19.92M	-31.92M	-19.77M
Operating Margin %	-125.19%	-150.04%	-26.12%	-31.32%	-88.88%	-92.96%	-139.54%	-141.3%	-158%	-116.31%
Operating Income Growth %	0.13%	0.17%	0.17%	-0.01%	-0.08%	-0.22%	-0.24%	-0.06%	-0.6%	0.38%
EBITDA+	-15.46M	-12.63M	-10.41M	-10.58M	-11.61M	-14.42M	-18.06M	-20.35M	-31.68M	-19.53M
EBITDA Margin %	-116.24%	-137.34%	-23.83%	-28.82%	-82.96%	-88.46%	-133.8%	-144.3%	-156.82%	-114.86%
EBITDA Growth %	0.14%	0.18%	0.18%	-0.02%	-0.1%	-0.24%	-0.25%	-0.13%	-0.56%	0.38%
D&A (Non-Cash Add-back)	1.19M	1.17M	1M	920K	829K	733K	775K	-424K	238K	246K
EBIT	-15.23M	-7.5M	-8.12M	-9.32M	-8.98M	-13.73M	-19.06M	-19.45M	-28.96M	-16.73M
Net Interest Income+	361K	129K	-51K	-470K	-338K	-453K	-67K	629K	0	4.61M
Interest Income	364K	129K	88K	32K	89K	219K	0	629K	0	5.19M
Interest Expense	3K	0	139K	502K	427K	672K	67K	0	0	585K
Other Income/Expense	1.42M	6.3M	3.16M	1.67M	3.04M	752K	-289K	477.81K	2.95M	2.45M
Pretax Income+	-15.23M	-7.5M	-8.26M	-9.81M	-9.53M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Pretax Margin %	-114.51%	-81.54%	-18.9%	-26.74%	-68.09%	-88.34%	-141.68%	-137.91%	-143.38%	-101.88%
Income Tax+	3K	0	0	2.19M	1.29M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.14%	1%	1%	1%	1%	1%
Net Income+	-15.23M	-7.5M	-8.26M	-9.81M	-10.83M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Net Margin %	-114.51%	-81.54%	-18.9%	-26.74%	-77.33%	-88.34%	-141.68%	-137.91%	-143.38%	-101.88%
Net Income Growth %	0.13%	0.51%	-0.1%	-0.19%	-0.1%	-0.33%	-0.33%	-0.02%	-0.49%	0.4%
Net Income (Continuing)	-15.23M	-7.5M	-8.26M	-9.83M	-9.4M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-34.05	-15.13	-12.67	-9.77	-2.97	-0.51	-0.45	-0.44	-0.60	-0.31
EPS Growth %	0.3%	0.56%	0.16%	0.23%	0.7%	0.83%	0.12%	0.02%	-0.36%	0.48%
EPS (Basic)	-34.05	-15.13	-12.67	-9.77	-2.97	-0.51	-0.45	-0.44	-0.60	-0.31
Diluted Shares Outstanding	447.25K	495.86K	651.72K	1M	3.64M	31.84M	47.34M	48.05M	48.59M	56.02M
Basic Shares Outstanding	447.25K	495.86K	651.72K	1M	3.64M	31.84M	47.34M	48.05M	48.59M	56.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.57M	6.94M	3.5M	3.8M	10.45M	40.31M	50.21M	36.32M	14.56M	4.18M
Cash & Short-Term Investments	8.91M	5.87M	2.11M	1.82M	8.78M	39M	48.27M	34.19M	13.07M	3.98M
Cash Only	2.12M	2.41M	1.41M	299K	1.47M	38.5M	32.09M	27.05M	5.44M	1.7M
Short-Term Investments	6.79M	3.46M	695K	1.53M	7.31M	501K	16.18M	7.14M	7.63M	2.28M
Accounts Receivable	0	0	24K	1.09M	820K	1.12M	1.64M	1.68M	1.18M	0
Days Sales Outstanding	-	-	20.05	1.09K	2.14K	2.52K	4.44K	4.34K	2.14K	-
Inventory	1.33M	0	0	0	0	0	0	0	-302K	0
Days Inventory Outstanding	302.87	-	-	-	-	-	-	-	-	-
Other Current Assets	0	764K	764K	0	0	184K	0	455K	302K	199K
Total Non-Current Assets+	12.23M	11.93M	10.7M	10.05M	9.77M	70.71M	7.49M	4.17M	4.83M	4.43M
Property, Plant & Equipment	11.24M	9.51M	8.59M	7.78M	7.27M	6.65M	4.2M	1.02M	824K	726K
Fixed Asset Turnover	0.01x	0.01x	0.05x	0.05x	0.02x	0.02x	0.03x	0.14x	0.25x	0.23x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	862K	872K	858K	912K	1.15M	1.5M	1.97M	1.94M	2.31M	2.59M
Long-Term Investments	0	0	0	-40.29M	-45.09M	15.38M	-25.02M	0	0	0
Other Non-Current Assets	134K	1.55M	1.26M	1.35M	1.35M	116K	1.32M	1.2M	1.69M	1.11M
Total Assets+	22.8M	18.87M	14.21M	13.85M	20.22M	111.02M	57.7M	40.49M	19.38M	8.61M
Asset Turnover	0.01x	0.00x	0.03x	0.03x	0.01x	0.00x	0.00x	0.00x	0.01x	0.02x
Asset Growth %	-0.23%	-0.17%	-0.25%	-0.03%	0.46%	4.49%	-0.48%	-0.3%	-0.52%	-0.56%
Total Current Liabilities+	2.43M	2.44M	2.71M	5.29M	1.13M	1.1M	673K	1.36M	8.65M	9.54M
Accounts Payable	1.21M	887K	741K	680K	472K	383K	198K	377K	6.44M	6.38M
Days Payables Outstanding	277.06	292.2	228.63	280.77	192.92	173.44	85.02	-324.54	55.99K	75.15K
Short-Term Debt	0	0	0	3.61M	214K	277K	0	0	0	2.31M
Deferred Revenue (Current)	0	0	0	806K	189K	0	0	0	0	0
Other Current Liabilities	0	0	0	0	309K	440K	0	1K	1.57M	1K
Current Ratio	4.34x	2.85x	1.29x	0.72x	9.27x	36.58x	74.61x	26.69x	1.68x	0.44x
Quick Ratio	3.80x	2.85x	1.29x	0.72x	9.27x	36.58x	74.61x	26.69x	1.72x	0.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	940K	2.8M	3.38M	6.18M	48.63M	147K	659K	495K	395K
Long-Term Debt	0	0	1.83M	0	3.91M	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.32M	2.22M	2.01M	112K	659K	495K	395K
Deferred Tax Liabilities	0	0	0	40.29M	44.56M	46.44M	23.71M	0	0	0
Other Non-Current Liabilities	0	940K	962K	1.06M	57K	180K	35K	0	0	0
Total Liabilities	2.43M	3.38M	5.5M	8.67M	7.31M	49.73M	820K	2.02M	9.15M	9.93M
Total Debt+	1K	0	1.83M	5.92M	6.38M	2.29M	149K	837K	718K	2.94M
Net Debt	-2.11M	-2.41M	423K	5.63M	4.91M	-36.22M	-31.94M	-26.22M	-4.72M	1.24M
Debt / Equity	0.00x	-	0.21x	1.15x	0.49x	0.04x	0.00x	0.02x	0.07x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-5550.00x	-	-82.13x	-22.90x	-29.14x	-22.55x	-281.16x	-	-	-33.80x
Total Equity+	20.37M	15.5M	8.7M	5.17M	12.91M	61.29M	56.88M	38.47M	10.23M	-1.32M
Equity Growth %	-0.19%	-0.24%	-0.44%	-0.41%	1.49%	3.75%	-0.07%	-0.32%	-0.73%	-1.13%
Book Value per Share	45.55	31.25	13.35	5.15	3.54	1.92	1.20	0.80	0.21	-0.02
Total Shareholders' Equity	20.37M	15.5M	8.7M	5.17M	12.91M	61.29M	56.88M	38.47M	10.23M	-1.32M
Common Stock	247K	24K	33K	49K	10K	42K	48K	48K	49K	66K
Retained Earnings	-293M	-300.5M	-308.76M	-318.57M	-328.11M	-341.97M	-361.1M	-380.55M	-409.51M	-426.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-97K	-5K	11K	-3K	0	-47K	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.05M	-7.38M	-7.94M	-10.64M	-9.07M	-10.37M	-13.96M	-16.11M	-21.27M	-14.89M
Operating CF Margin %	-120.7%	-80.22%	-18.17%	-28.99%	-64.76%	-63.61%	-103.44%	-114.24%	-105.28%	-87.58%
Operating CF Growth %	-0.15%	0.54%	-0.08%	-0.34%	0.15%	-0.14%	-0.35%	-0.15%	-0.32%	0.3%
Net Income	-15.23M	-7.5M	-8.26M	-9.81M	-9.53M	-14.4M	-19.13M	-19.45M	-28.96M	-17.32M
Depreciation & Amortization	1.19M	1.3M	1.01M	878K	792K	733K	805K	256K	238K	246K
Stock-Based Compensation	181K	410K	571K	929K	853K	1.04M	1.57M	954K	243K	686K
Deferred Taxes	0	57K	-17K	-1.4M	-891K	-96K	-2.32M	197K	5.84M	0
Other Non-Cash Items	378K	-1.68M	-2.38M	845K	255K	1.75M	4.24M	964K	310K	1.2M
Working Capital Changes	-2.57M	29K	1.13M	-2.08M	-543K	605K	895K	966K	1.06M	296K
Change in Receivables	0	0	-24K	-1.07M	274K	40K	34K	-35K	492K	1.18M
Change in Inventory	-1.33M	-1.33M	0	0	-647K	0	0	35K	0	0
Change in Payables	-196K	-326K	566K	166K	-207K	-89K	-185K	179K	0	-60K
Cash from Investing+	6.35M	2.92M	2.73M	92K	-6.15M	-9.16M	-631K	10.99M	-832K	4.71M
Capital Expenditures	-490K	-454K	-69K	-127K	-365K	-595K	-633K	-271K	-585K	-18K
CapEx % of Revenue	3.68%	4.93%	0.16%	0.35%	2.61%	3.65%	4.69%	1.92%	2.9%	0.11%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1.13M	0	-573K	-347K	0	0	-631K
Cash from Financing+	9.66M	4.76M	4.21M	9.44M	16.39M	56.56M	8.19M	80K	485K	6.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	4.76M	-102K	4.52M	0	0	0	0	0	3.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.54M	-7.83M	-8.01M	-10.77M	-9.43M	-10.96M	-14.6M	-16.38M	-21.85M	-14.91M
FCF Margin %	-124.38%	-85.15%	-18.33%	-29.34%	-67.37%	-67.26%	-108.13%	-116.16%	-108.18%	-87.68%
FCF Growth %	-0.13%	0.53%	-0.02%	-0.34%	0.12%	-0.16%	-0.33%	-0.12%	-0.33%	0.32%
FCF per Share	-36.99	-15.80	-12.29	-10.72	-2.59	-0.34	-0.31	-0.34	-0.45	-0.27
FCF Conversion (FCF/Net Income)	1.05x	0.98x	0.96x	1.08x	0.84x	0.72x	0.73x	0.83x	0.73x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-67.13%	-41.83%	-68.25%	-141.43%	-119.75%	-38.81%	-32.37%	-40.79%	-118.94%	-388.69%
Return on Invested Capital (ROIC)	-60.73%	-66.05%	-77.08%	-86.54%	-65.22%	-52.99%	-56.5%	-80.36%	-269.48%	-546.09%
Gross Margin	-1101.5%	-1104.35%	-170.71%	-140.87%	-537.86%	-394.48%	-529.63%	400.71%	79.21%	81.76%
Net Margin	-11451.13%	-8154.35%	-1889.93%	-2673.84%	-7732.86%	-8834.36%	-14168.15%	-13790.78%	-14337.62%	-10188.24%
Debt / Equity	0.00x	-	0.21x	1.15x	0.49x	0.04x	0.00x	0.02x	0.07x	-
Interest Coverage	-5550.00x	-	-82.13x	-22.90x	-29.14x	-22.55x	-281.16x	-	-	-33.80x
FCF Conversion	1.05x	0.98x	0.96x	1.08x	0.84x	0.72x	0.73x	0.83x	0.73x	0.86x
Revenue Growth	-32.49%	-30.83%	375%	-16.02%	-61.85%	16.43%	-17.18%	4.44%	43.26%	-15.84%

Revenue by Segment

	2020	2021	2022
Clinical Treatment Programs - US	-	-	141K
Clinical Treatment Programs - US Growth	-	-	-
Clinical Treatment Programs U S	-	135K	-
Clinical Treatment Programs U S Growth	-	-	-

Revenue by Geography

	2020	2021	2022
United States	144K	-	-
United States Growth	-	-	-
Europe	19K	-	-
Europe Growth	-	-	-

Frequently Asked Questions

Growth & Financials

AIM ImmunoTech Inc. (AIM) reported $0.1M in revenue for fiscal year 2024. This represents a 30% decrease from $0.2M in 2011.

AIM ImmunoTech Inc. (AIM) saw revenue decline by 15.8% over the past year.

AIM ImmunoTech Inc. (AIM) reported a net loss of $15.8M for fiscal year 2024.

Dividend & Returns

AIM ImmunoTech Inc. (AIM) has a return on equity (ROE) of -388.7%. Negative ROE indicates the company is unprofitable.

AIM ImmunoTech Inc. (AIM) had negative free cash flow of $13.3M in fiscal year 2024, likely due to heavy capital investments.